REVB Stock Performance, Insider Transaction and News

REVB - Revelation Biosciences, Inc.

Market Cap	5.02M	P/E	0.01	EPS this Y	-2,047.20%	Ern Qtrly Grth	-
Income	-15.9M	Forward P/E	-0.52	EPS next Y	51.10%	50D Avg Chg	-13.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-79.00%
Dividend	N/A	Price/Book	0.39	EPS next 5Y	-	52W High Chg	-96.00%
Recommedations	2.00	Quick Ratio	1.09	Shares Outstanding	3.76M	52W Low Chg	15.00%
Insider Own	0.14%	ROA	-42.07%	Shares Float	1.64M	Beta	0.19
Inst Own	1.35%	ROE	-253.32%	Shares Shorted/Prior	25.65K/313.73K	Price	0.83
Gross Margin	-	Profit Margin	-	Avg. Volume	232,706	Target Price	14.45
Oper. Margin	-	Earnings Date	Nov 7	Volume	105,693	Change	-1.16%

Healthcare | Biotechnology | United States

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Revelation Biosciences, Inc. News

12/03/24	Sector Update: Health Care Stocks Mixed Late Afternoon
12/03/24	Top Midday Decliners
12/03/24	Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
12/02/24	REVB Gets FDA Go Ahead
12/02/24	Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
11/12/24	Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
11/11/24	REVB Results Set Stage for Future Growth
11/08/24	Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
09/24/24	Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
08/21/24	Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
08/12/24	REVB: Bolsters Cash Amid Positive Trial Results
08/09/24	Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
07/08/24	REVB Releases Positive Test Results—Potential Catalyst
06/24/24	Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
06/24/24	Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
06/13/24	Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
05/13/24	REVB: In Great Position For Testing
05/10/24	Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
03/25/24	REVB Begins Trials with Good Cash on Hand
03/22/24	Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

REVB Chatroom

OptionDayTrader4Profit Posted - 14 hours ago

$REVB Adding like 100 shares each drop.

WolfofFraudStreet Posted - 16 hours ago

$REVB Added this one to my do not buy list. Crazy warrants are insane. Class A , class be, c d, e f g, I think they are going to issue all the letters of the Alphabet all the way down to Z warrants

GTM86 Posted - 17 hours ago

$REVB like I said. Expect further downside. Sabby and Armistice are involved in this one. Whenever you see any one of those names, understand that company is not a long term investment and will eventually burn.

CryptoSenderX Posted - 18 hours ago

$REVB pump will be unexpected and astonishing like for $DRUG $STEC $MNPR 🪐

Andrea1987 Posted - 21 hours ago

$REVB less than 2M market cap. Kinda ridiculous

Unknown_Stuntman Posted - 22 hours ago

$REVB no bottom to this hole

NVDAMillionaire Posted - 1 day ago

$REVB Revelation Biosciences: A Promising Immunology-Focused Biotech Navigating Challenges https://beyondspx.com/article/revelation-biosciences-a-promising-immunology-focused-biotech-navigating-challenges

new_jack Posted - 1 day ago

$REVB buy zone.

BALR0G Posted - 1 day ago

$REVB This stock loves making new bagholders Dont be another number

RAGC Posted - 1 day ago

$REVB news 👇👇 https://www.sec.gov/Archives/edgar/data/1810560/000095017024133661/2024_special_meeting_pre.htm

Sam131313 Posted - 1 day ago

$REVB added more

543688Ireland Posted - 1 day ago

$REVB Still excited about this one.

GaryGherkins Posted - 1 day ago

$REVB 1 year return is negative 97%, Merry Christmas!!

DowntowinCJ Posted - 1 day ago

$TNON jumping in investing first time with $TNON Almost like $GWAV and $REVB so much upside ... Let's go 🚀🔥

DowntowinCJ Posted - 1 day ago

$REVB let's go ... This thing is ready 🚀🔥

RedHottie Posted - 1 day ago

$REVB

Mohammed_kas Posted - 1 day ago

$REVB Any news about the medications?

EP2024 Posted - 1 day ago

@The_Assassin What do you make of $REVB

The_Assassin Posted - 1 day ago

$MTEM $SBFM $GWAV $REVB $MIGI dont say i didnt give ya. I freaking gave yall the bangers

Mohammed_kas Posted - 1 day ago

$REVB Maybe with good news he goes up.

Travelling Posted - 1 day ago

$smx bought more to hold - sold yesterday at .70, watching $revb $dbgi holding small position in $sos (sold 3/4 recently) will buy dips

Tiffers16 Posted - 1 day ago

$REVB $ASST $LGMK 👀

Bio_IsTheGame22 Posted - 1 day ago

$REVB

Bio_IsTheGame22 Posted - 1 day ago

$REVB 🧨🧨

VrtcIl Posted - 1 day ago

If $REVB breaks 1, the next target is 2. Keep in mind that after it breaks over a level it should not fall below once again and stay there. Price: 0.57 Float: 6.2M Short Float: 10.0 % 💰 Dollar Volume: 1.0K ℹ️ USA | Biotechnology

Eclipse24 Posted - 1 day ago

$REVB

Brokechump Posted - 1 day ago

$REVB

Hallochen Posted - 1 day ago

$MTEM $RLMD $SBFM $REVB $MOBX

Bigmoney4me Posted - 2 days ago

$REVB on $PRFX ⚠️⚠️⚠️⚠️⚠️ wouldn’t change out CFO and CEO if not for problem with Lotus

Hallochen Posted - 2 days ago

$RLMD ATENTION LOW PRICE 💰💰💰💰💰💰💰💰💰💰💰 Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on the development of REL-P11 for metabolic disease Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024 $MTEM $REVB $SBFM $MOBX

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
TIDMARSH GEORGE F	Director Director	Oct 16	Sell	0.6501	1,845	1,199	27,771	10/18/23
TIDMARSH GEORGE F	Director Director	Sep 28	Sell	0.69	1,429	986	42,096	10/02/23
TIDMARSH GEORGE F	Director Director	Sep 14	Sell	0.74	25,500	18,870	39,348	09/18/23
TIDMARSH GEORGE F	Director Director	Feb 25	Buy	1.60	20,000	32,000	467,156	02/28/22
TIDMARSH GEORGE F	Director Director	Feb 08	Buy	2.55	31,000	79,050	447,156	02/10/22
TIDMARSH GEORGE F	Director Director	Feb 04	Buy	2.46	50,000	123,000	1,523,335	02/08/22